NeoPharm at strong buy rating from JMP

NeoPharm, Inc. was reiterated at strong buy with a $19 price target by JMP Securities analyst Charles C. Duncan. The company's interim phase 1 data of cintredekin besudotox (CBtox) in newly diagnosed glioma patients showed promise in terms of safety and tolerability in combination with radiation and temozolomide treatment. Shares of the Lake Forest, Ill., biopharmaceutical company were down 8 cents, or 1.03%, at $7.67 on volume of 161,803 shares versus the three-month running average of 290,998 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.